References
- MercierCCiccoliniJProfiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapyClin Colorectal Cancer20066428829617241513
- SaifMWSyrigosKMehraRMattisonLKDiasioRBDeficiency dehydrogenase (DPD) in GI malignancies: experience of 4-yearsPakistan J Med Sci2007236832839
- LeicherLWde GraafJCCoersWTascilarMde GrootJWTolerability of capecitabine monotherapy in metastatic colorectal cancer: a real-world studyDrugs R D201717111712427848234
- SaifMWKatirtzoglouNASyrigosKNCapecitabine: an overview of the side effects and their managementAnticancer Drugs200819544746418418212
- RosmarinDPallesCPagnamentaAA candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMSGut201564111112024647007
- MilanoGHighlight on DPYD gene polymorphisms and treatment by capecitabineScand J Clin Lab Invest Suppl2016245S30S3327454530
- CortejosoLGarcía-GonzálezXGarcíaMIGarcía-AlfonsoPSanjurjoMLópez-FernándezLACost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidinesPharmacogenomics201617997998427248859
- TerrazzinoSCargninSDel ReMDanesiRCanonicoPLGenazzaniAADPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysisPharmacogenomics201314111255127223930673
- ThomasFHennebelleIDelmasCGenotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratioClin Pharmacol Ther201699223524226265035
- CaudleKEThornCFKleinTEClinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosingClin Pharmacol Ther201394664064523988873
- DesmetFOHamrounDLalandeMCollod-BéroudGClaustresMBéroudCHuman Splicing Finder: an online bioinformatics tool to predict splicing signalsNucleic Acids Res2009379e6719339519
- van KuilenburgABMeijerJMaurerDSevere fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicingBiochim Biophys Acta201718633721730
- Etienne-GrimaldiMCBoyerJCBeroudCNew advances in DPYD genotype and risk of severe toxicity under capecitabinePLoS One2017125e017599828481884
- van KuilenburgABHaasjesJRichelDJClinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD geneClin Cancer Res20006124705471211156223
- FlegerMWillomitzerJMeinsmaRDihydropyrimidine dehydrogenase deficiency: metabolic disease or biochemical phenotype?JIMD Rep201737495428275972
- LoganayagamAArenas HernandezMCorriganAPharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicityBr J Cancer2013108122505251523736036
- KleiblZFidlerovaJKleiblovaPInfluence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapyNeoplasma200956430331619473056
- MeulendijksDHenricksLMSonkeGSClinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient dataLancet Oncol201516161639165026603945